A pharmaceutical treatment may offer patients an alternative to the usual surgical removal of basal cell carcinomas, according to a presentation at the annual meeting of the American Academy of Dermatology in New Orleans. The results
BETHESDA, Md--Delta-amino-levulinic acid (ALA), a compound found in cells throughout the body, holds potential as an active drug in photodynamic therapy and could provide an alternative to surgery for patients with basal and squamous cell carcinomas, R. Rox Anderson, MD, said at the General Motors Cancer Research Foundation conference.
Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib... More »
Eccentric darker pigmentation in this small asymptomatic lesion strongly suggests malignant melanoma. This patient had a history of non-melanoma skin cancer, but was unaware of the questionable... More »
Skin cancer is the single most common form of cancer, accounting for more than 75% of all cancer diagnoses. More than 1 million cases of squamous cell and basal cell carcinomas are diagnosed annually,... More »
This uncommon benign entity closely mimics squamous cell carcinoma, superficial basal cell carcinoma, and advanced actinic keratoses. The lichenoid keratosis does not transform into skin cancer. More »
A small punch biopsy showed basal cell carcinoma with focal hypermelanosis. The underlying erythema and punctuate superficial dark black pigmentation strongly suggested a dysplastic nevus or even a... More »
The US Food and Drug Administration (FDA) announced the approval of vismodegib (Erivedge), for the treatment of advanced basal cell carcinoma, the most common type of skin cancer, for patients who are... More »